US Blacklist Unlikely to Stop Pharma Ties with Chinese Firms
Analysts suggest the Pentagon's blacklist of WuXi AppTec will have minimal impact on multinational pharmaceutical companies' collaborations with Chinese firms. Cost efficiency remains a primary driver for outsourcing to China.